Market Monitor

Bristol-Myers Squibb Co. (NY: BMY)
43.30 USD  +0.53 (+1.24%)
Official Closing Price  /  Updated: 6:40 PM EDT, May 17, 2013  /  Add to My Watchlist      
(BMY) Community Analysis from
May 18, 2013
(Stock Blog Hub, 5/14/13)
Merck & Co. Inc. (MRK) recently joined forces with Bristol-Myers Squibb (BMY) to conduct a phase II study with their hepatitis C virus...(read more)
(Investment U, 2/8/13)
Will This Drug Be The Next Hit? Is it Time to Load Up on Some Gold? The "Slap in the Face" Award: Shanghai Edition...
(Stock Blog Hub, 1/15/13)
The Medicines Company (MDCO) recently received good news with the company announcing positive results on its phase III candidate, cangrelor. Cangrelor is being...(read more)
Bristol-Myers Squibb Company (BMY) Company Overview

This article is about Bristol-Myers Squibb. For the article on the company with ticker BMS, see Bemis Company (BMS).

Bristol-Myers Squibb (NYSE: BMY) is one of the world's largest pharmaceutical companies by total sales. Bristol-Myers Squibb offers treatments for cardiovascular disease, HIV/AIDS, hepatitis, cancer, and rheumatoid arthritis. Cancer treatments in particular represent a major portion of the company's long-term growth potential and have historically been a strong suit of Bristol-Myers Squibb. The company's top three blockbuster drugs (annual sales >$1 billion) are blood thinner Plavix, Abilify for schizophrenia, and Reyataz for HIV. In FY 2010, BMY generated revenues of $19.5B and net earnings of $3.1B.[1]

(Read more at Wikinvest )

Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here